Life Sciences

  • January 22, 2026

    Patent Office Beats La Jolla Pharma's Application Denial Suit

    A Virginia federal judge on Wednesday upheld a U.S. Patent and Trademark Office decision that denied patent applications from drug developer La Jolla Pharma LLC claiming a unique dosage and delivery method of a drug the company markets to treat low blood pressure, finding the claims are all anticipated or obvious.

  • January 22, 2026

    House Report Claims Evidence of CVS Antitrust Violations

    House Judiciary Committee staffers said Wednesday that they'd uncovered "a pattern of anticompetitive activity" in CVS Health tactics aimed at coercing independent pharmacies into avoiding working with online services the company saw as a threat to its own pharmacy and pharmacy benefit manager businesses.

  • January 22, 2026

    Supplement Cos. Challenge FDA Health Claim Denials

    A group of health supplement companies hit the U.S. Food and Drug Administration with a suit in D.C. federal court Wednesday alleging regulators wrongly denied them approval to make over 100 distinct claims concerning the health benefits of their products.

  • January 22, 2026

    Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents

    The Federal Circuit on Thursday refused to reconsider decisions invalidating Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, turning aside the German drugmaker's claim that the court set an unjust new rule that means inventors' work can later be used against them.

  • January 22, 2026

    Hologic Faces Del. Class Suit Over $18.3B Sale Disclosures

    Citing alleged failures to make news about litigation settlements public ahead of a proposed $18.3 billion company sale, a pension fund stockholder of women's health-focused tech company Hologic Inc. has sued for a Delaware Court of Chancery hold on the deal pending disclosures or damages awards.

  • January 22, 2026

    3rd Circ. Says Medical Pot Contract May Violate Federal Law

    The Third Circuit on Thursday vacated a medical cannabis company's win in a lawsuit filed by a consultant claiming that it had stolen his trade secrets for growing marijuana samples, finding it couldn't decide the appeal because the parties' contract might have violated federal drug law.

  • January 22, 2026

    AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test

    A California federal judge has thrown out artificial intelligence diagnostics company Tempus AI's patent infringement suit against medical test-maker Guardant Health, finding claims in the patents weren't patent-eligible to begin with.

  • January 22, 2026

    Simpson Thacher Adds Quinn Emanuel Atty To New SF Office

    A Quinn Emanuel Urquhart & Sullivan LLP attorney who worked on high-profile intellectual property matters representing Google and Jane Street Group has joined Simpson Thacher & Bartlett LLP as partner in its newly opened San Francisco office, the firm announced Thursday.

  • January 22, 2026

    Medical Cannabis Co. Says Data Breach Didn't Lead To Injury

    An Ohio medical cannabis company has said a consolidated class action in federal court should be dismissed as it doesn't allege any of the plaintiffs' data was accessed in a data breach or that the breach could be linked to any real damage.

  • January 22, 2026

    Investors Drop LA Law Firm From Bioscience Fraud Suit

    A group of investors including a "Toy Story" screenwriter pursuing an $87 million fraud suit against a bioscience company in California state court has agreed to drop claims against a California law firm and its name partner, with the firm in turn withdrawing an anti-SLAPP motion it filed in the suit.

  • January 21, 2026

    Holmes Seeks Trump Clemency For Theranos Fraud Sentence

    Former Theranos CEO Elizabeth Holmes has asked President Donald Trump to commute an 11-year prison sentence she's been serving for defrauding investors with bogus blood-testing technology, according to the U.S. Department of Justice's Office of the Pardon Attorney.

  • January 21, 2026

    CVS, UnitedHealth, Express Scripts Duck PBM Antitrust Suit

    A Missouri federal judge has thrown out a proposed class action accusing the country's three largest pharmacy benefit managers — owned by CVS, UnitedHealth Group and Cigna Group — of inflating prescription costs through their rebating practices.

  • January 21, 2026

    Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal

    A Washington Court of Appeals panel expressed reluctance to award Bristol-Myers Squibb Co.'s bid to send a former worker's age discrimination case to arbitration Wednesday, while also casting some doubt on the ex-employee's stance that the arbitration pact she signed was invalid.

  • January 21, 2026

    Medtronic 'Blocked' Surgical Device Competition, Jury Told

    An executive at Applied Medical Resources Corp. on Tuesday told a California federal jury considering antitrust claims against Medtronic Inc. that a surgical device his company introduced a decade ago had great success in Europe but was "blocked" in the U.S. by Medtronic's practice of "bundling" products.

  • January 21, 2026

    Texas AG Launches Investigation Into Vaccine Incentives

    The Texas attorney general launched what it characterized as a sweeping, multi-industry investigation into financial incentives for medical providers to recommend childhood vaccines, saying providers regularly dish out vaccines that "are not proven to be safe or necessary."

  • January 21, 2026

    Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

    A Delaware federal judge found Wednesday that MSN Pharmaceuticals Inc. infringed a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto, saying the issue has already been litigated before.

  • January 21, 2026

    Allergan Says Fed. Circ.'s Ax Of $39M Win Misread Record

    A Federal Circuit decision reversing a $39 million verdict against Sandoz in Allergan's suit accusing it of infringing an eyelash growth drug patent misunderstood the evidence and was based on an "indisputably false" premise, Allergan said in a petition for rehearing Tuesday.

  • January 21, 2026

    Teva's Inconsistent Args In IUD Trial 'Troubling,' Judge Says

    Teva Pharmaceuticals quickly ran afoul of a Georgia federal judge Wednesday in its first trial over alleged defects in its Paragard IUD, as the court chastised the drugmaker's attorneys over "very troubling" inconsistencies in their opening statements to jurors.

  • January 21, 2026

    FTC Mulling Deal With Express Scripts In PBM Case

    The Federal Trade Commission is considering a potential settlement with Express Scripts in the agency's case accusing the country's three largest pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • January 21, 2026

    Fla. Dispensary Exposed Patient Data Via Google, Suit Says

    A Florida man is suing a dispensary website in federal court, alleging it has violated federal health confidentiality laws by using Google Analytics Pixel on its website, which he said intercepts and collects private information for use in advertising.

  • January 20, 2026

    Justices To Clarify What's Fair Game With 'Skinny Labels'

    A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.

  • January 20, 2026

    Orrick Expands IP Team With Cadwalader, Kirkland Litigators

    Orrick Herrington & Sutcliffe LLP has beefed up its intellectual property litigation team with three new partners experienced in counseling technology and life sciences clients, adding two former Cadwalader Wickersham & Taft LLP litigators in New York and a former Kirkland & Ellis LLP partner in Los Angeles.

  • January 20, 2026

    Dentsply Can't Shed Investors' Aligner Injury Cover-Up Suit

    Dental supply company Dentsply Sirona Inc. must face a proposed investor class action alleging it covered up medical injuries and other issues affecting an aligner business it acquired for $1 billion, and caused shareholder losses when the injuries were revealed and the acquisition collapsed.

  • January 20, 2026

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.

  • January 20, 2026

    Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy

    The Federal Circuit on Tuesday revived an inventor's patent infringement suit against DePuy Synthes Cos., ruling that the persuasiveness of expert testimony that was excluded by a lower court is best left for the jury.

Expert Analysis

  • Litigation Funding Could Create Ethics Issues For Attorneys

    Author Photo

    A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.